Health experts say vaccine race is similar to wilderness law

LONDON – High-income countries have adopted a “wilderness regime” approach to ensure the supply of future coronavirus vaccines, according to a global health, governance and infectious diseases expert.

Suari Moon, co-director of the Global Health Center of the Institute of Geneva on CNBC Monday, said that the amount of vaccines available to low-income countries was likely to have significant consequences in the coming months.

There is growing optimism that the coronovirus vaccine may help end the coronovirus epidemic that has claimed more than 1.31 million lives worldwide.

Modern said on Monday that preliminary late-stage test data showed that its vaccine was more than 94% effective at stopping Kovid-19. Last week, Pfizer and BioNotech said preliminary analysis of their vaccine candidate showed that it was more than 90% effective in preventing coronavirus infection.

The race to deliver a vaccine coincides with a scramble to secure future supplies, before their safety and efficacy have been established.

“I think from a public health point of view what we want to see is that the first people to get vaccinated are the ones at greatest risk of infection and the greatest risk of getting seriously ill. And it’s both True. In countries and countries, “Moon told CNBC’s” Street Signs Europe “on Monday.

“Unfortunately, what we have been seeing for the last few months is actually a rule of forest type situation where we have the largest resources mainly in Europe, North America, Japan for example … the rest of the world. Vaccines are much safer than parts.

He said all countries should make arrangements to ensure that health workers, people with underlying medical conditions, and older people arrive with priority for any potential vaccines.

Rich countries ‘bet on more than one horse’

Most countries around the world have vaccinated COVAX, Covid-19 vaccines, GAVI, the Alliance for Epidemiological Preparedness (CEPI) and the WHO-led coalition.

COVAX aims to provide 2 billion vaccines of coronavirus by the end of 2021 to protect high-risk populations worldwide. In the long run, the alliance is designed to provide adequate doses for countries that cover 20% of their population, while self-financed countries may purchase different levels of population.

On Thursday, October 22, 2020, a motorcyclist wears a protective mask while sitting by the roadside at the Sabarmati Riverfront in Ahmedabad, India. Prime Minister Narendra Modi said that his government will ensure that all 1.3 billion people will reach nationwide as soon as the Kovid-19 vaccine is ready.

Sumit Dayal | Bloomberg Getty Images

“The COVAX facility is a real ray of sunshine, I should say, what has happened in a fairly dark situation in terms of global vaccine penetration,” Moon said.

“One of the big problems is that many countries are not only relying on COVAX, as I mentioned, rich countries are placing bets on more than one horse,” she continued. “They are getting their vaccine supplies through bilateral channels, through direct agreements with companies, and they are also saying: ‘We will do Covax.”

Finally, Moon said that this means that although there is a lot of good intentions and significant amounts to support equal access to future vaccines, there is not really a very large amount of supply.

“Right now, we do not expect that more than 10% or 15% of the population say that developing countries may be able to use vaccines via COVAX.”

GAVI said on Friday that more than $ 2 billion had been raised in support of the GAVI COVAX Advance Market Commitment, which supports 92- and middle-income economies’ access to a safe and effective Kovid-19 vaccine. Is a financing mechanism designed for.

The group said, however, that at least $ 5 billion would be needed next year to ensure equitable distribution of future vaccines.

‘Countries strengthen when they work together’

Data compiled by researchers at Duke University’s Global Health Innovation Center suggest that 9.5 billion doses of the Kovid-19 vaccine have already been reserved, even before any candidates have been approved for the market.

High-income countries account for more than half of all confirmed purchases, the data shows, while the US accounts for about one-sixth of advance market commitments (AMCs). The US has ordered more than 1 billion doses from half a dozen drug manufacturers.

Direct deals made primarily by high-income countries result in a small slice of the pie available for equal global allocation.

World Health Organization (WHO) Director-General Tedros Adnom Ghibeyius attends a daily press briefing on the novel COVID-19 caused by the novel coronavirus in a WHO audience on March 11, 2020 in Geneva.

Fabrice Kofrini | AFP | Getty Images

WHO Director General Tedros Adnom Ghebius said via Twitter earlier this month that Kovid-19’s response “shows that countries are stronger when they work together through multilateral platforms.”

“Solutions should be shared as global public goods based on equal and affordable access to all – these are ethical, public health and economic imperatives,” said Tedros.


Leave a Reply